BDAZ - I remembered seeing the article on Seeking Alpha that you are referring to as IL-1B for some reason had stuck in my mind. Thank you for jogging my memory as to where I saw it. 

With the NovoNordisc news of them having success in their trial that targeted this inflammation marker, I would think that if RVX sees success in this BETonMACE trial that they will blow the market away. From previous presentations they showed a potential market value based on an annual medication cost of just $2000 with a proviso of up to $5000.

This should bode very well for RVX-208 as the PCSK9's come in around $15K to $18K annually and the NovoNordisc one that comes in around $60K.

With a stated 6-8 year lead on the market it would be a spectacular win for RVX to have a positive BETonMACE trial result. I look forward to hearing the DSMB's next comments and the results of the Futility Analysis along with whatever else they have in the hooper.

tada